pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The October 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:
- Two new drug products have initiated pCPA negotiations, for a total of 46 active negotiations;
- Seven negotiations have been completed/closed, for a total of 177 joint completed/closed negotiations; and
- No new drug products were added to the “No pCPA Negotiations” list, for a total of 55 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
- No new drug products were added to the “Negotiations considered by each province/territory” list for a total of 13 drug products that were individually considered at the provincial-territorial level.
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since September 30, 2017 is as follows:
- Three new drug products have received recent CDEC or pERC recommendations, for a total of approximately 18 products under pCPA Consideration
Please see below for more details.
- Two new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
Brand Name |
Generic Name |
Manufacturer |
Indication |
Recommendation/Notification to Implement Date |
Time to Negotiation* (days) |
|---|---|---|---|---|---|
Gazyva |
obinutuzumab | Hoffmann-La Roche Ltd. | Follicular Lymphoma | June 19, 2017 | 118 days |
Lynparza (resubmission) |
olaparib | AstraZeneca Canada Inc. | Ovarian Cancer | October 5, 2017 | 10 days |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
- Seven negotiations have been completed/closed since the last update, for a total of 177 joint completed/closed negotiations.
- Four negotiations were completed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration * (days)
|
|---|---|---|---|---|---|
Erelzi |
Etanercept | Sandoz Canada Inc. | Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis and rheumatoid arthritis | April, 2017 | 183 days |
Humira |
Adalimumab | AbbVie Corporation | Hidradenitis suppurativa | July, 2017 | 92 days |
Prolia |
Denosumab | Amgen Canada | osteoporosis | December, 2015 | 670 days |
Repatha |
Evolocumab | Amgen Canada | Primary hyperlipidemia and mixed dyslipidemia | July, 2016 | 457 days |
-
- Three negotiations were closed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration * (days)
|
|---|---|---|---|---|---|
Invokamet |
Canagliflozin/metformin/
hydrochloride |
Janssen Inc. | Type 2 Diabetes | May, 2017 | 153 days |
Kalydeco |
ivacaftor | Vertex Pharmaceuticals Canada | Cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation | January, 2015 | 1,004 days |
Kevzara |
Sarilumab | Sanofi Genzyme | Rheumatoid Arthritis | July, 2017 | 92 days |
*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation
Based on information collected by MORSE Consulting:
- Three new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 18 products under pCPA Consideration.
Brand Name |
Generic Name |
Manufacturer |
Indication |
Final Recommendation/Notification to Implement |
|---|---|---|---|---|
Izba |
travoprost ophthalmic solution | Novartis Pharmaceuticals Canada Inc. | open-angle glaucoma | October 25, 2017 |
Dysport Therapeutic |
abobotulinumtoxinA | IPSEN Biopharmaceuticals Canada, Inc | Upper limb spasticity | October 24, 2017 |
Darzalex |
Daratumumab | Janssen Canada Inc. | Multiple myeloma | October 23, 2017 |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
